Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
2 "Contrast media"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Basic and Translational Research
Article image
PUM2 Lowers HDAC9 mRNA Stability to Improve Contrast-Induced Acute Kidney Injury by Attenuating Oxidative Stress and Promoting Autophagy
Wei Chen, Hengcheng Lu, Wenni Dai, Hao Li, Yinyin Chen, Guoyong Liu, Liyu He
Diabetes Metab J. 2026;50(4):672-687.   Published online September 10, 2025
DOI: https://doi.org/10.4093/dmj.2024.0396
  • 8,231 View
  • 100 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Contrast-induced acute kidney injury (CIAKI) is the third leading cause of hospital-acquired acute kidney injury and diabetes mellitus (DM) has been identified as a risk factor for CIAKI. However, the molecular mechanism underlying DM-CIAKI remains unclear and requires further investigation.
Methods
Mouse and cell models of DM-CIAKI were established. Kidney function was evaluated by measuring biochemical indicators and using hematoxylin and eosin staining. Gene and protein abundance was assessed using real-time quantitative reverse transcription polymerase chain reaction, immunohistochemistry, immunofluorescence, and Western blotting. Glutathione peroxidase, superoxide dismutase, and malondialdehyde were measured using commercial kits, and reactive oxygen species were detected using a dihydroethidium (DHE) probe and the 2ʹ,7ʹ-dichlorofluorescein diacetate (DCFH-DA) method. Apoptosis in tissues and cells was evaluated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). Cell viability and proliferation were measured using Cell Counting Kit-8 and 5-ethynyl-2ʹ-deoxyuridine (EdU) assays. The interaction between pumilio RNA binding family member 2 (PUM2) and histone deacetylase 9 (HDAC9) was validated using RNA immunoprecipitation (RIP) and RNA pull-down assays.
Results
PUM2 expression was markedly reduced in DM-CIAKI models, whereas HDAC9 expression was notably increased. Subsequently, PUM2 silencing aggravated kidney injury in DM-CIAKI mice by enhancing oxidative stress and suppressing autophagy, whereas HDAC9 inhibition or HDAC9 silencing had the opposite effects. Mechanistically, PUM2 could suppressed the stability of HDAC9 mRNA, thereby attenuating HDAC9 expression. Furthermore, HDAC9 overexpression abolished PUM2 overexpression-mediated inhibition of oxidative stress and promotion of autophagy in high glucose- and contrast media-treated human kidney-2 (HK-2) cells.
Conclusion
PUM2 overexpression suppressed oxidative stress and promoted autophagy to alleviate renal injury in DM-CIAKI by interacting with HDAC9 mRNA, which mediated HDAC9 and mRNA degradation and inhibited HDAC9 expression.

Citations

Citations to this article as recorded by  
  • Purpurin Rescues Contrast-Induced Acute Rat Kidney Injury via Inducing Autophagy and Inhibiting Apoptosis
    Kangxu He, Xiaoying Sun, Xinhui Pan, Xiaoda Yang, Qi Wang, Kai Liao
    Pharmaceuticals.2026; 19(1): 116.     CrossRef
  • Rubia cordifolia L. Dichloromethane Extract Ameliorates Contrast-Induced Acute Kidney Injury by Activating Autophagy via the LC3B/p62 Axis
    Xiaoying Sun, Kangxu He, Guanzhong Chen, Xiaoda Yang, Xinhui Pan, Kai Liao
    Molecules.2026; 31(2): 316.     CrossRef
  • Research progress on risk factors and early predictors of contrast-induced nephropathy
    Yemei Ma
    American Journal of Translational Research.2026; 18(4): 2795.     CrossRef
Review
Guideline/Fact Sheet
Article image
Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
Diabetes Metab J. 2020;44(1):3-10.   Published online February 21, 2020
DOI: https://doi.org/10.4093/dmj.2020.0004
  • 39,339 View
  • 678 Download
  • 20 Web of Science
  • 21 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   

The safety of metformin use for patients with type 2 diabetes mellitus (T2DM) and advanced kidney disease is controversial, and more recent guidelines have suggested that metformin be used cautiously in this group until more definitive evidence concerning its safety is available. The Korean Diabetes Association and the Korean Society of Nephrology have agreed on consensus statements concerning metformin use for patients with T2DM and renal dysfunction, particularly when these patients undergo imaging studies using iodinated contrast media (ICM). Metformin can be used safely when the estimated glomerular filtration rate (eGFR) is ≥45 mL/min/1.73 m2. If the eGFR is between 30 and 44 mL/min/1.73 m2, metformin treatment should not be started. If metformin is already in use, a daily dose of ≤1,000 mg is recommended. Metformin is contraindicated when the eGFR is <30 mL/min/1.73 m2. Renal function should be evaluated prior to any ICM-related procedures. During procedures involving intravenous administration of ICM, metformin should be discontinued starting the day of the procedures and up to 48 hours post-procedures if the eGFR is <60 mL/min/1.73 m2.

Citations

Citations to this article as recorded by  
  • Association between diabetes duration and hyperuricemia: Korea National Health and Nutrition Examination Survey 2016 to 2021
    Kyuho Kim, Kyungdo Han, In Young Kim, Kyuna Lee, Yu-Bae Ahn, Seung-Hyun Ko, Jae-Seung Yun
    The Korean Journal of Internal Medicine.2026; 41(1): 143.     CrossRef
  • The Role of Combining Exercise with Pharmacologic Management of Chronic Kidney disease: From Sodium-Glucose Co-Transporter-2 and Glucagon-Like Peptide-1 to Broader Therapeutic Strategies
    Thomas J. Wilkinson, Greg Biddle, Emily James
    Nephron.2026; 150(8): 533.     CrossRef
  • Beyond Diabetes: Continuous Glucose Monitoring as a Candidate Precision Tool for Cardiovascular Prevention and Healthy Longevity—A Hypothesis-Generating Narrative Review
    Cristina Văcărescu, Dragos Cozma
    Medicina.2026; 62(8): 1513.     CrossRef
  • Metformin and risk factors for chronic kidney disease in a European population based on Mendelian randomization
    Xiaopei Liu, Xingyao Li, Peng An, Qi Gao, Yanhong Zhao, Xingmin Shi, Xili Wu
    Renal Failure.2025;[Epub]     CrossRef
  • Sulfur-Rich Garlic Extract (DNR) as a Promising Natural Therapeutic for Diabetic Nephropathy: Evidence from a db/db Mouse Model
    Ju Hee Park, Byung Sik Cho, Xue Bi Zhou, Richard Kyung, Myong Jo Kim
    International Journal of Molecular Sciences.2025; 26(20): 10184.     CrossRef
  • Metformin and Myo-Inositol: A Comparative Analysis
    Michele Russo, Mario Montanino Oliva, Maurizio Nordio, Giuseppina Porcaro, Vittorio Unfer
    Gynecologic and Obstetric Investigation.2025; 91(4): 411.     CrossRef
  • Distribution and elimination kinetics of midazolam and metabolites after post-resuscitation care: a prospective observational study
    Wonjoon Jeong, Jung Sunwoo, Yeonho You, Jung Soo Park, Jin Hong Min, Yong Nam In, Hong Joon Ahn, So Young Jeon, Jang Hee Hong, Ji Hye Song, Hyein Kang, My Tuyen Thi Nguyen, Jaehan Kim, Changshin Kang
    Scientific Reports.2024;[Epub]     CrossRef
  • Prediction of glycosylated hemoglobin level in patients with cardiovascular diseases and type 2 diabetes mellitus with respect to anti-diabetic medication
    Alisher Ikramov, Shakhnoza Mukhtarova, Raisa Trigulova, Dilnoza Alimova, Saodat Abdullaeva
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Clinical Management of Type II DM in patients Showing Progressive Increase in the Creatinine Level – A Cross-sectional Study
    Prabhudatta Mohapatra, Durga Madhab Kar, Karmajeet Rath, Abhisek Pal
    Research Journal of Pharmacy and Technology.2024; : 2719.     CrossRef
  • Trends in Antidiabetic Drug Use and Safety of Metformin in Diabetic Patients with Varying Degrees of Chronic Kidney Disease from 2010 to 2021 in Korea: Retrospective Cohort Study Using the Common Data Model
    Sung Hwan Joo, Seungwon Yang, Suhyun Lee, Seok Jun Park, Taemin Park, Sang Youl Rhee, Jae Myung Cha, Sandy Jeong Rhie, Hyeon Seok Hwang, Yang Gyun Kim, Eun Kyoung Chung
    Pharmaceuticals.2024; 17(10): 1369.     CrossRef
  • Determinants of vitamin B12 deficiency in patients with type-2 diabetes mellitus — A primary-care retrospective cohort study
    Andrew Kien Han Wee, Rehena Sultana
    BMC Primary Care.2023;[Epub]     CrossRef
  • Risk factors for post-contrast acute kidney injury in patients sequentially administered iodine- and gadolinium-based contrast media on the same visit to the emergency department: a retrospective study
    Changshin Kang, Soo Hyun Han, Jung Soo Park, Dae Eun Choi
    Kidney Research and Clinical Practice.2023; 42(3): 358.     CrossRef
  • Guideline for the diagnosis and treatment of diabetes mellitus in patients with transfusion-dependent thalassemia
    Mohammad E. Khamseh, Mojtaba Malek, Nahid Hashemi-madani, Fariba Ghassemi, Neda Rahimian, Amir Ziaee, Mohammad Reza Foroughi-Gilvaee, Pooya Faranoush, Negin Sadighnia, Ali Elahinia, Mohammad Reza Rezvany, Mohammad Faranoush
    Iranian Journal of Blood and Cancer.2023; 15(4): 293.     CrossRef
  • Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future
    Filipe Ferrari, Rafael S. Scheffel, Vítor M. Martins, Raul D. Santos, Ricardo Stein
    American Journal of Cardiovascular Drugs.2022; 22(4): 363.     CrossRef
  • Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes Therapy.2021; 12(1): 171.     CrossRef
  • Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000–2019
    Kyung Ae Lee, Heung Yong Jin, Yu Ji Kim, Yong-Jin Im, Eun-Young Kim, Tae Sun Park
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Continuous use of metformin in patients receiving contrast medium: what is the evidence? A systematic review and meta-analysis
    Ting-Wan Kao, Kuo-Hua Lee, Wing P. Chan, Kang-Chih Fan, Che-Wei Liu, Yu-Chen Huang
    European Radiology.2021; 32(5): 3045.     CrossRef
  • Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)
    Eugene Han, Hye Soon Kim
    Diabetes & Metabolism Journal.2021; 45(6): 972.     CrossRef
  • KRCP's past and future path
    Tae-Hyun Yoo
    Kidney Research and Clinical Practice.2020; 39(3): 233.     CrossRef
  • Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease—A Systematic Review and Meta-Analysis
    Yao Hu, Min Lei, Guibao Ke, Xin Huang, Xuan Peng, Lihui Zhong, Ping Fu
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Pharmacotherapy for patients with diabetes mellitus
    Joon Ho Moon, Soo Lim
    Journal of the Korean Medical Association.2020; 63(12): 766.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer
TOP